Search Results for: 155

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11, […]

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results Read More »

Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

— Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for

Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019 Read More »

Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results

— Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis — — Two Ribaxamase and Two SYN-010 Presentations to be Included at Digestive Disease Week (DDW 2017) — — Conference Call Today, May 4, 2017, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 4, 2017 /PRNewswire/

Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study

— Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis — — Poster Presentations Planned for ECCMID and ESPID Conferences, Including Data from Prophylaxis Study — ROCKVILLE, Md., April 19, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome

Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study Read More »

Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results

— Positioned to Initiate Phase 3 Clinical Trial for SYN-010 for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in 2H 2016 — — Two SYN-010 Posters Scheduled for Presentation at Digestive Disease Week (DDW 2016), Including Additional Positive Results from Two Phase 2 Clinical Trials — — Conference Call Today, May 5, 2016,

Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights

— Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and

Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights Read More »

Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update

— Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate — ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for

Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update Read More »